A study finds that hyperimmune plasma is effective against Covid if used early from the onset of the disease
The New England Journal of Medicine ( NEJM ) yesterday, March 30, 2022, published the final results of a nationwide multi-center study conducted by researchers at Johns Hopkins Medicine and Johns Hopkins Bloomberg School of Public Health showing that plasma from patients who have recovered from COVID-19 and whose blood contains antibodies to SARS-CoV-2, the causative virus, is an effective and safe option as an early outpatient treatment for the disease.
Research has shown that high titer COVID hyperimmune plasma (rich in antibodies), when given to COVID-19 outpatients within nine days of a positive test, reduced the need for hospitalization for more than half of the predominantly unvaccinated outpatients of the study.
The United States Food and Drug Administration (FDA) currently authorizes this plasma as a treatment option for outpatients with autoimmune diseases or receiving drugs that depress the immune system and for all hospitalized patients with early stage COVID-19. .
The results were first presented in a preprint published in MedRxiv on December 21, 2021.
“Based on our findings and conclusions, which are now validated through the peer-review process, we encourage healthcare professionals to keep SARS-CoV-2 antibody-rich blood plasma available in their blood banks as part of the arsenal of treatment against early stage COVID-19, ”says study co-author David Sullivan, MD, professor of molecular microbiology and immunology at Johns Hopkins Bloomberg School of Public Health with a joint appointment in infectious diseases at Johns Hopkins University School of Medicine.
"We believe that the best role for hyperimmune plasma is to extend its use to early outpatient treatment when other therapies, such as monoclonal antibodies or drugs, are not readily available, such as in low- and middle-income countries – or ineffective, such as with SARS-CoV-2 variants that are resistant to certain monoclonal antibodies, ”adds Sullivan.
Study finds convalescent plasma may be effective early covid-19 therapy (medicalxpress.com)
A thought and an ideal hug to Professor De Donno.
Thanks to our Telegram channel you can stay updated on the publication of new articles of Economic Scenarios.
The article A study finds that hyperimmune plasma is effective against Covid if used early from the onset of the disease comes from ScenariEconomici.it .
This is a machine translation of a post published on Scenari Economici at the URL https://scenarieconomici.it/uno-studio-rileva-che-il-plasma-iperimmune-e-efficace-contro-il-covid-se-usato-precocemente-dallinsorgenza-della-malattia/ on Thu, 31 Mar 2022 18:21:21 +0000.